Research programme: IL-7 targeting CAR-T cell therapy - OSE Immunotherapeutics
Latest Information Update: 17 Jul 2024
At a glance
- Originator OSE Immunotherapeutics
- Developer Memorial Sloan-Kettering Cancer Center; OSE Immunotherapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Haematological malignancies